Cell therapy image from Wikimedia Commons
The cell and gene therapy market continues to advance, thanks to its promise to treat cancers and other severe diseases. While the pandemic has had a negative impact on companies specializing in cell and gene therapies, it has also catalyzed interest in cold-chain logistics while also highlighting the promise of new therapy types.
Organizations interested in expanding their focus on cell and gene therapies can learn from best practices from organizations specializing in high-stake logistics.
Push for standards and collaborationThe initial focus on transporting mRNA vaccines at below-normal temperatures “highlighted the need for some sort of standardization,” said Ray Hornung, senior manager, logistics and emergency preparedness at Be The Match BioTherapies (Minneapolis).
Ray Hornung
While t…